Clinical trial
Anti-Estrogen Therapy for Hereditary Hemorrhagic Telangiectasia A Double-Blind…
NCT00375622 · Rabin Medical Center, Other · Completed
Key facts
| NCT number | NCT00375622 |
|---|---|
| Title | Anti-Estrogen Therapy for Hereditary Hemorrhagic Telangiectasia A Double-Blind Placebo-Controlled Clinical Trial |
| Lead sponsor | Rabin Medical Center, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hereditary Hemorrhagic Telangiectasia |
| Intervention type | Drug |
| Interventions | Tamoxifen |
| Enrollment | 60 |
| Start date | Feb 1, 2005 |
| Completion | Jun 1, 2006 |
| First posted | Sep 13, 2006 |
| Last update posted | Sep 13, 2006 |
| Countries | Israel |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: